PMID- 25298213
OWN - NLM
STAT- MEDLINE
DCOM- 20150221
LR  - 20211021
IS  - 1757-2215 (Print)
IS  - 1757-2215 (Electronic)
IS  - 1757-2215 (Linking)
VI  - 7
DP  - 2014 May 7
TI  - The feasibility and clinical effects of dendritic cell-based immunotherapy 
      targeting synthesized peptides for recurrent ovarian cancer.
PG  - 48
LID - 10.1186/1757-2215-7-48 [doi]
AB  - BACKGROUND: Despite the increased rate of complete response to initial 
      chemotherapy, most patients with advanced ovarian cancer relapse and succumb to 
      progressive disease. Dendritic cell (DC)-based immunotherapy has been developed 
      as a novel strategy for generating antitumor immunity as part of cancer 
      treatments. The present study aimed to assess the feasibility and clinical 
      effects of DC therapy for recurrent ovarian cancer (ROC). METHODS: This 
      retrospective study included 56 ROC patients who initially received standard 
      chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 
      2 institutions between March 2007 and August 2013. The adverse events (AEs) and 
      clinical responses were examined. RESULTS: No serious treatment-related AEs were 
      observed. Seventy one percent of the enrolled patients developed an immunologic 
      response. The median survival time (MST) from ROC diagnosis was 30.4 months, and 
      that from the first vaccination was 14.5 months. Albumin levels of >/=4.0 g/dL and 
      lactate dehydrogenase levels of <200 IU/L before vaccination were identified as 
      significant independent factors by multivariate Cox proportional hazard analysis. 
      The MST from the first vaccination in patients with albumin levels of >/=4.0 and 
      <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease 
      control rates were 36% and 15%, respectively. CONCLUSIONS: Our results 
      demonstrated the feasibility and potential clinical effectiveness of DC-based 
      immunotherapy for ROC patients. Additionally, a good nutritional status might be 
      an important factor for further clinical effects.
FAU - Kobayashi, Masanori
AU  - Kobayashi M
FAU - Chiba, Asako
AU  - Chiba A
FAU - Izawa, Hiromi
AU  - Izawa H
FAU - Yanagida, Eri
AU  - Yanagida E
FAU - Okamoto, Masato
AU  - Okamoto M
FAU - Shimodaira, Shigetaka
AU  - Shimodaira S
FAU - Yonemitsu, Yoshikazu
AU  - Yonemitsu Y
FAU - Shibamoto, Yuta
AU  - Shibamoto Y
FAU - Suzuki, Noboru
AU  - Suzuki N
FAU - Nagaya, Masaki
AU  - Nagaya M
CN  - DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140507
PL  - England
TA  - J Ovarian Res
JT  - Journal of ovarian research
JID - 101474849
RN  - 0 (Cancer Vaccines)
RN  - 0 (Peptides)
RN  - 0 (WT1 Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Cancer Vaccines/administration & dosage/immunology
MH  - Combined Modality Therapy
MH  - Dendritic Cells/*immunology/metabolism
MH  - Female
MH  - Humans
MH  - *Immunotherapy/adverse effects
MH  - Lymphocyte Count
MH  - Lymphocyte Subsets/immunology
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Ovarian Neoplasms/diagnosis/*immunology/mortality/pathology/*therapy
MH  - Peptides/chemical synthesis/*immunology/metabolism
MH  - Retrospective Studies
MH  - T-Cell Antigen Receptor Specificity/immunology
MH  - Treatment Outcome
MH  - WT1 Proteins/immunology
MH  - Young Adult
PMC - PMC4108140
EDAT- 2014/10/10 06:00
MHDA- 2015/02/24 06:00
PMCR- 2014/05/07
CRDT- 2014/10/10 06:00
PHST- 2014/01/25 00:00 [received]
PHST- 2014/04/30 00:00 [accepted]
PHST- 2014/10/10 06:00 [entrez]
PHST- 2014/10/10 06:00 [pubmed]
PHST- 2015/02/24 06:00 [medline]
PHST- 2014/05/07 00:00 [pmc-release]
AID - 1757-2215-7-48 [pii]
AID - 10.1186/1757-2215-7-48 [doi]
PST - epublish
SO  - J Ovarian Res. 2014 May 7;7:48. doi: 10.1186/1757-2215-7-48.